Clinical Trial Update: A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. [Phase 1, Phase 2]

View source ↗

Summary

Astellas reports results from a Phase 1/2 study of ASP2215 (gilteritinib) in combination with induction and consolidation chemotherapy for newly diagnosed FLT3-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Flt3-mutated Acute Myeloid Leukemia

Drugs mentioned

• ASP2215

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-16